Invesaro

Stocks Comparison

NewGenIvf vs Progyny: revenue, profit, margins and growth compared

NewGenIvf brought in $23.7M of revenue in fiscal 2025, Progyny $1.3B in fiscal 2025. Revenue changed by +336.3% at NewGenIvf and +10.4% at Progyny on the year before, so NewGenIvf grew faster. NewGenIvf kept 41.7% of its revenue as net profit, Progyny 4.5%. Free cash flow was -$11.1M at NewGenIvf and $191.8M at Progyny.

Side by side, latest fiscal year

NIVFPGNY
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$23.7M$1.3B
Revenue growth+336.3%+10.4%
Net income$9.9M$58.5M
Net margin41.7%4.5%
Free cash flow-$11.1M$191.8M
Free cash flow margin-46.7%14.9%
Earnings per share (diluted)$3.04$0.65
Cash$758.6K$112.2M
Debtn/an/a
Price to earningsn/a39.1
Market value$3.3M$2B
Dividend yieldn/an/a
Rank by revenue in sector#425 of 646 · Health care#134 of 646 · Health care

Over the years

Revenue
NIVF FY2021: $4.1MNIVF FY2023: $5.9MNIVF FY2023: $5.1MNIVF FY2024: $5.4MNIVF FY2025: $23.7MPGNY FY2019: $105.4MPGNY FY2019: $229.7MPGNY FY2020: $344.9MPGNY FY2021: $500.6MPGNY FY2022: $786.9MPGNY FY2023: $1.1BPGNY FY2024: $1.2BPGNY FY2025: $1.3BFY19FY20FY21FY22FY23FY24FY25
NIVF $23.7MPGNY $1.3B
Net income
NIVF FY2021: -$533NIVF FY2023: $458.7KNIVF FY2023: $130.2KNIVF FY2024: -$524.6KNIVF FY2025: $9.9MPGNY FY2019: $661KPGNY FY2019: -$8.6MPGNY FY2020: $46.5MPGNY FY2021: $65.8MPGNY FY2022: $30.4MPGNY FY2023: $62MPGNY FY2024: $54.3MPGNY FY2025: $58.5MFY19FY20FY21FY22FY23FY24FY25
NIVF $9.9MPGNY $58.5M
Net margin
NIVF FY2021: -0.0%NIVF FY2023: 7.7%NIVF FY2023: 2.5%NIVF FY2024: -9.7%NIVF FY2025: 41.7%PGNY FY2019: 0.6%PGNY FY2019: -3.7%PGNY FY2020: 13.5%PGNY FY2021: 13.1%PGNY FY2022: 3.9%PGNY FY2023: 5.7%PGNY FY2024: 4.7%PGNY FY2025: 4.5%FY19FY20FY21FY22FY23FY24FY25
NIVF 41.7%PGNY 4.5%
Revenue growth
NIVF FY2023: +44.3%NIVF FY2023: -13.6%NIVF FY2024: +5.8%NIVF FY2025: +336.3%PGNY FY2019: +117.9%PGNY FY2020: +50.1%PGNY FY2021: +45.2%PGNY FY2022: +57.2%PGNY FY2023: +38.3%PGNY FY2024: +7.2%PGNY FY2025: +10.4%FY19FY20FY21FY22FY23FY24FY25
NIVF +336.3%PGNY +10.4%
Free cash flow
NIVF FY2021: $1.4MNIVF FY2023: $1.6MNIVF FY2023: -$1.8MNIVF FY2024: -$8.3MNIVF FY2025: -$11.1MPGNY FY2019: $1.7MPGNY FY2019: -$4.5MPGNY FY2020: $35.2MPGNY FY2021: $23.9MPGNY FY2022: $77.2MPGNY FY2023: $185.2MPGNY FY2024: $173.7MPGNY FY2025: $191.8MFY19FY20FY21FY22FY23FY24FY25
NIVF -$11.1MPGNY $191.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about NewGenIvf and Progyny

Which is bigger by revenue, NewGenIvf or Progyny?

Progyny is bigger by revenue: $1.3B in fiscal 2025, against $23.7M for NewGenIvf in fiscal 2025.

Which keeps more of its revenue as profit, NewGenIvf or Progyny?

NewGenIvf had a net margin of 41.7% in fiscal 2025; Progyny had 4.5% in fiscal 2025.

Which grew revenue faster, NewGenIvf or Progyny?

In their latest fiscal years revenue changed by +336.3% at NewGenIvf and +10.4% at Progyny.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies